ProCE Banner Activity

SOLO-1: OS With 7-Yr Follow-up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation Who Received Maintenance Olaparib

Slideset Download
Conference Coverage
The 7-year follow-up from SOLO-1 shows continued survival benefit for patients with newly diagnosed advanced ovarian cancer who were treated with maintenance olaparib for up to 2 years vs placebo.

Released: September 15, 2022

Expiration: September 14, 2023

No longer available for credit.
Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from


Bristol Myers Squibb

Exelixis, Inc.

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp.